---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report. Covers Cost-effectiveness evidence. 60 evidence topics quoted from 33 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics/cost-effectiveness"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report

<a id="economic-information-and-modeling-report"></a>

## 4 Economic Information and Modeling Report

<a id="heading-4.1"></a>

### 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

#### Summary: published cost-effectiveness analyses of AMT-130 and of disease-modifying therapy in Huntington's disease

- A cost-effectiveness analysis of tominersen and AMT-130 in Huntington's disease (HD) used a Markov model with four health states (early, middle, late, and death) from a modified societal perspective, with a 1-year cycle length, a 3% annual discount rate, and 30 annual cycles. All patients entered in the early stage, and utilities for both treatments were assumed equal to standard of care because trial-based utility data are not yet available. Lacking established cost data, the authors assumed the cost of AMT-130 to be the list price of Zolgensma, applied a 15% payer discount to estimate a one-time dose at $1,806,250, and used an AMT-130 administration cost of $23,516. Compared with standard of care, AMT-130 increased costs by $1.49 million and QALYs by 5.23, for an incremental cost-effectiveness ratio of $285,703 per QALY gained; the ratio for tominersen was $2.28 million per QALY gained. The authors applied a willingness-to-pay threshold of $500,000/QALY gained because HD is a rare disease. AMT-130 had an 80% probability of being cost-effective at $350,000/QALY gained, 30% at $250,000 per QALY gained, and 0% for both treatments at $100,000–150,000 per QALY gained. Adding the value of hope changed the AMT-130 ratio to $236,540 per QALY gained. The ratios were most sensitive to drug costs and to early and middle-stage utilities, and the authors state that the model relied heavily on the assumption of sustained benefit beyond the data.
- A U.S. decision-modeling framework for future disease-modifying treatments estimated lifetime costs of HD of $508,200 for the PFD population, $1.15 million for SF1 individuals, and $1.07 million for SF2 individuals; the authors did not assign a price to a disease-modifying treatment because the treatments under development vary in mechanism, route of administration, and once versus recurrent therapy.
- A United Kingdom model fitted a continuous-time hidden Markov disease progression model with five states to Enroll-HD data, and its cost modelling showed that indirect costs such as state benefits and lost gross domestic product contribution could drive the societal cost of HD over health and social care costs.
- In a PTC Therapeutics-funded analysis of eladocagene exuparvovec-tneq, the administration cost, a proxy for the cost of the stereotactic procedure, was $106,030 and the incremental cost per QALY ranged from $199,007–$224,104.

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/); [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/); [Pollard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11576117/); [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799622/)

<a id="topic-4.1-2"></a>

#### Summary: ICER assessment of AMT-130 and its model analysis plan

- Scope and timeline: the Institute for Clinical and Economic Review (ICER) is assessing the comparative clinical effectiveness and value of AMT-130 for Huntington's disease, with public discussion at a Midwest CEPAC meeting in March 2027. The population of focus is adults with early symptomatic Huntington's disease, the comparator is usual symptomatic care, and the draft scope set publication of the model analysis plan for November 16, 2026. The revised scope proposes assessing AMT-130 under an adaptation of the ICER Value Framework for single and short-term therapies, with analyses from the health care system perspective and the modified societal perspective and outcomes of years of independent living gained, life-years gained, QALYs gained, and evLYs. The revised scope states that uniQure had been unwilling to speak with ICER and, at uniQure's request, that uniQure did not participate in the process and did not review or approve the methodology, findings, or conclusions.
- Framework: under ICER's single and short-term therapy adaptations, analyses include a 50/50 shared savings model, in which 50% of lifetime health system cost offsets are assigned to the health system, and a cost-offset cap model, in which cost offsets are capped at $150,000 per year, the top of the ICER range for value-based pricing for an additional QALY. A threshold analysis for the durability of effect estimates the duration of benefit AMT-130 would need to reach standard cost-effectiveness thresholds.
- Structure: the model analysis plan describes a cohort Markov model comparing AMT-130 added onto usual symptomatic care with usual symptomatic care alone over a lifetime horizon, from a health care sector perspective in the base case, with a one-year cycle and costs and outcomes discounted at 3% per year. Health states follow Shoulson and Fahn staging by Total Functional Capacity (TFC): stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), stage 4 (TFC 1-2), and stage 5 (TFC 0). All patients enter in stage 1, based on a baseline TFC of 12.1 in the pivotal trial's primary analysis, and the target population is adults with early manifest HD, with inputs from the high-dose arm.
- Natural history and treatment effect: on usual symptomatic care, TFC declines at a constant rate of -0.23 TFC/year, from a linear regression of Enroll-HD cohort B TFC scores at baseline, 12, 24, 36 and 48 months. On AMT-130, progression follows the observed TFC trajectory up to 48 months; afterwards, the base case applies the usual care decline rate reduced by 61%, the treatment effect on TFC at 48 months, or rates estimated by the clinical team, and durability remains over the lifetime. A scenario applies a 44% slowing of TFC progression based on cUHDRS, and other scenarios address natural history, durability, waning, outcome-based payment arrangements, and a premanifest population.
- Other inputs: mortality follows U.S. general population life tables with stage-specific excess mortality (0.000 in SF stage 1 to 0.146 in SF stage 5); utilities range from 0.78 in SF stage 1 to 0.22 in SF stages 4 and 5; costs are in 2025 US dollars. Peri-operative and treatment-related serious adverse events are applied as one-time costs at rates of 16.4% ($10,645) and 19.2% ($19,501). All-cause background costs from Medicaid claims are $28,454 in early, $69,016 in middle, and $118,889 in late HD, and indirect costs are $85,656, $133,500, and $112,816.
- Price, outcomes, and budget impact: the placeholder price is $2,600,000, the midpoint of analyst estimates from $1,700,000 to $3,500,000, and the administration price of $24,138.83 is based on the estimates of an earlier AMT-130 model. Outcomes include years of independent life and years free of full-time care; probabilistic sensitivity analysis uses 1,000 simulations, and threshold analyses for drug costs span $50,000, $100,000, $150,000, and $200,000 per QALY and evLY gained. Budget impact is estimated over a five-year time horizon for 25,811 eligible patients, of whom 20% initiate treatment each year (5,162 patients per year), against a threshold of approximately $709 million per year.

Source: [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-gene-therapy-for-huntingtons-disease/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf); [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf); [ICER research protocol (2026)](https://osf.io/download/eyjx6/); [ICER single and short-term therapies adaptations (2022)](https://icer.org/wp-content/uploads/2022/12/ICER_SST_FinalAdaptations_122122.pdf); [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-3"></a>

#### Summary: price basis, other gene therapy prices, and payment models

- In June, Leerink analysts estimated a U.S. price of $1.7 million and worldwide sales of $2.5 billion in 2030 if AMT-130 is approved. The ICER placeholder price of $2,600,000 rests on estimates from $1,700,000 by Leerink Partners to $2,500,000 - $3,500,000 by IPD analytics. uniQure's annual report states that third-party payers and ICER increasingly challenge prices and examine budget impact and cost-effectiveness, and that the CMS GENEROUS Model requires rebates aligned with Most Favored Nation pricing to participating state Medicaid programs.
- Prices of other products: Zolgensma, a one-time treatment, $2.125 million list price ($425,000 per year for five years); the gene therapy Hemgenix, $3.5 million list price, for which ICER had used a $4 million placeholder price and found a Health Benefit Price Benchmark of $2.93 million to $2.96 million; Roctavian, $2.9 million wholesale acquisition cost; the gene therapy Elevidys, $3.2 million wholesale acquisition cost; the gene therapy Beqvez, $3.5 million; eladocagene exuparvovec-tneq, $3,950,000 U.S. wholesale acquisition cost. BioMarin announced that it will voluntarily remove Roctavian from the market, and Pfizer is ending global development and commercialization of Beqvez.
- Payment models: Novartis' AveXis worked with payers on five-year outcomes-based pacts and pay-over-time options for Zolgensma. BioMarin offered an outcomes-based warranty for Roctavian reimbursing up to 100% of wholesale acquisition cost on a prorated basis if response is lost in the first four years, and will honor existing outcomes-based agreements after withdrawal. Pfizer launched a warranty program for Beqvez based on durability of response, and CSL Behring offered a substantial rebate for Hemgenix if patients return to prophylactic factor IX during the first 3 1/2 years. One publication on gene therapy payment groups value-based contracts into milestone-based rebates, warranties, and performance-based installment payments, and names patients changing insurers and Medicaid Best Price provisions, which apply to all value-based contracts except warranties, as barriers.
- CMS Cell and Gene Therapy Access Model: a multi-year, voluntary model for states and manufacturers that tests a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies in Medicaid, initially focused on gene therapy for sickle cell disease, with 34 state participants and 2 manufacturer participants; states began participation between January 2025 and January 2026.

Source: [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/); [ICER model analysis plan (2026)](https://osf.io/download/puega/); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [Helfand (2019)](https://www.fiercepharma.com/pharma/novartis-slaps-2m-plus-pricetag-newly-approved-gene-therapy-zolgensma); [Myshko (2022)](https://www.managedhealthcareexecutive.com/view/fda-approves-gene-therapy-for-hemophilia-b); [Myshko (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-2-9-million-gene-therapy-for-hemophilia-a); [Blank (2023)](https://www.managedhealthcareexecutive.com/view/first-gene-therapy-for-duchenne-priced-at-3-2-million); [Myshko (2024)](https://www.managedhealthcareexecutive.com/view/fda-approves-pfizer-s-gene-therapy-for-beqvez-for-hemophilia); [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799622/); [BioMarin statement, ROCTAVIAN market withdrawal (2026)](https://www.biomarin.com/news/company-statements/biomarin-voluntarily-withdraws-roctavian-from-the-market/); [Liu (2025)](https://www.fiercepharma.com/pharma/pfizer-empties-gene-therapy-portfolio-discontinues-hemophilia-treatment-beqvez); [Pfizer press release, BEQVEZ approval (2024)](https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec); [Hagen (2023)](https://www.managedhealthcareexecutive.com/view/manufacturers-adopt-no-cure-no-pay-pricing-for-hemophilia-gene-therapy); [Phares et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11609966/); [CMS Cell and Gene Therapy Access Model (2026)](https://www.cms.gov/priorities/innovation/innovation-models/cgt)

<a id="topic-4.1-4"></a>

#### Summary: eligible population inputs and budget impact evidence

- The report holds no budget impact model for AMT-130; every leaf of its Budget Impact Model section reads No evidence found.
- ICER eligible population: approximately 40,000 people with Huntington's disease in the U.S. in 2020 (a prevalence rate of approximately 0.012%), approximately 62.7% of whom are in SF stage 1 or 2, applied to approximately 342 million people averaged over 2026-2030, gives 25,811 eligible patients, with 20% initiating treatment in each of the five years (5,162 patients per year). The exploratory preclinical population is 100,000 people (approximately 200,000 at risk multiplied by the 50% likelihood of inheriting the mutation), with 20,000 initiating treatment per year.
- Prevalence and stage distribution: in a study population of 38.4 million individuals who met a continuous enrollment requirement, the prevalence rate was 6.7 per 100,000 in 2020 and 9.4 per 100,000 in 2024. In British Columbia, prevalence was 13.7 per 100,000 in the general population. In an insurance database of over 67 million enrollees, 1.18% of those diagnosed were 20 years old or less. In one study, most participants were in TFC stages I–III, with 41.3% in stage II (n = 845 in stage I, n = 1068 in stage II, n = 540 in stage III, n = 116 in stage IV, and n = 15 in stage V).
- Other population inputs: pooled incidence was 0.48 cases per 100,000 person-years; median survival time in one cohort was 12.4 years; and in one study, 49.9% of people with Huntington's disease received neurologist care in a calendar year.
- Budget impact method: ICER will use the placeholder price of $2,600,000 and threshold prices at $50,000 to $200,000 per evLY gained, with undiscounted costs over five years, against a potential budget impact threshold of approximately $709 million per year for 2026-2027. uniQure lists increased diagnosis due to genetic testing and disease-modifying treatment availability, and an increase in addressable patient segments, as potential long-term growth levers.
- Reference analysis: in a CSL Behring-funded budget impact analysis of etranacogene dezaparvovec priced at $3,500,000 in a hypothetical 1-million-member plan over 5 years, 1.8 people were eligible and the cumulative budget impact was $848,509, with incremental annual costs of $79,824 to $271,435 and per-member per-month costs of $0.007 to $0.023; results were sensitive only to the uptake assumptions.

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/); [Frisch et al. (2026)](https://www.jmir.org/2026/1/e100284); [Fisher and Hayden (2014)](https://pubmed.ncbi.nlm.nih.gov/24151181/); [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/); [Furr Stimming et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089624/); [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/); [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/); [Ogilvie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316193/); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [Wilson et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293766/)

<a id="topic-4.1-5"></a>

#### Health technology assessment: ICER assessment page and public meeting

> “An assessment of ifezuntrigene inilparvovec”
> “Main Review March 25, 2027 MIDWEST CEPAC”
> “The Midwest CEPAC 2027 public meeting on ifezuntrigene inilparvovec for Huntington’s Disease.”
> “The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review.”

Source: [ICER Huntington's disease assessment page (2026)](https://icer.org/assessment/huntingtons-disease-2026/)

<a id="topic-4.1-6"></a>

#### Health technology assessment: ICER revised scope, single and short-term therapy framework

> “We propose to assess AMT-130 under an adaptation of the ICER Value Framework for treatments of high-impact “single and short-term therapies” (SSTs), because we believe it may meet the following criteria defined as:”
> “The therapy can eradicate a disease or condition or produce sustained major health gains that can halt the progression of significant illnesses.”
> “Following formal public comment and discussions with stakeholders, ICER will make a final decision on whether the therapy meets these criteria and will be assessed using an adapted approach.”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-4.1-7"></a>

#### Health technology assessment: ICER revised scope, perspective and Shoulson and Fahn health states

> “Analyses will be conducted from the health care system perspective and the modified societal perspective.”
> “The model will use Shoulson and Fahn staging based on Total Functional Capacity (TFC) scores to define health states capturing distinct levels of clinical progression.”
> “This staging was selected as published cost and utility estimates are currently available for TFC based staging; no equivalent estimates were identified stratified by composite Unified Huntington’s Disease Rating Scale (cUHDRS).”
> “The health outcome of each intervention will be evaluated in terms of years of independent living gained, life-years gained, QALYs gained, and evLYs.”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-4.1-8"></a>

#### Health technology assessment: manufacturer participation in the ICER review

> “To date, the manufacturer uniQure has been unwilling to speak with ICER and asks ICER to”
> “that uniQure did not participate in the process and did not review or approve the methodology, findings, or conclusions.”

Source: [ICER revised scope (2026)](https://icer.org/wp-content/uploads/2026/09/ICER_Huntingtons-Disease_Revised-Scope_For-Publication_092126.pdf)

<a id="topic-4.1-9"></a>

#### Health technology assessment: ICER research protocol, research question and review components

> “What is the net health benefit of AMT-130 versus usual symptomatic care (treatment for movement disorders [e.g., chorea], psychiatric and mood symptoms, physical therapy, etc.)?”
> “To that aim, the assessment is informed by two research components: a systematic review of the existing evidence and an economic evaluation.”

Source: [ICER research protocol (2026)](https://osf.io/download/eyjx6/)

<a id="topic-4.1-10"></a>

#### ICER model analysis plan: aim, comparator, perspective, and framework adaptations

> “The primary aim of this analysis will be to estimate the cost-effectiveness of AMT-130 for HD using a Cohort Markov Model.”
> “The model will compare AMT-130 added onto usual symptomatic care, to usual symptomatic care alone, over a lifetime horizon.”
> “The base case analysis will take a health care sector perspective (i.e., focus on direct medical care costs only), and patient and caregiver productivity impacts and other indirect costs and effects will be considered in the modified societal perspective analysis.”
> “Scenario analyses reflecting an optimistic and conservative benefit of AMT-130.”
> “Threshold analysis for the durability of effect to determine the duration of beneficial effect (e.g., cure) patients receiving AMT-130 would need to achieve standard cost-effectiveness thresholds (e.g., $150,000/QALY).”
> “50/50 shared savings model in which 50% of lifetime health system cost offsets from AMT-130 are “assigned” to the health system instead of being entirely assigned to AMT-130.”
> “Cost-offset cap model in which health system cost offsets generated by AMT-130 are capped at $150,000 per year but are otherwise assigned entirely to AMT-130.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-11"></a>

#### ICER model analysis plan: model structure and health states

> “We will develop a de novo decision analytic model for this evaluation, informed by key clinical trials and prior relevant economic models.”
> “Costs and outcomes will be discounted at 3% per year.”
> “Model cycle length will be one year, based on what was observed in prior published economic models/clinical data.”
> “Health states will be defined using the Total Functional Capacity (TFC) scale, following the Shoulson and Fahn (SF) staging system”
> “stage 1 (TFC 11-13), stage 2 (TFC 7-10), stage 3 (TFC 3-6), stage 4 (TFC 1-2), and stage 5 (TFC 0).”
> “The TFC scale measures the functional ability in people with HD across five domains: occupation, finances, domestic chores, activities of daily living, and level of care required, with a score of 13 representing full/independent function and 0 representing a total loss of function.”
> “SF stages 1 and 2 correspond to early-stage HD, stage 3 to middle, and stages 4 and 5 to late.”
> “All patients will enter the model in stage 1, based on the baseline TFC reported in the pivotal trial’s primary analysis of 12.1.”
> “Patients remain in the model until they die.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-12"></a>

#### ICER model analysis plan: key model assumptions

> “Treatment effect is modeled using the TFC scale, assuming effects on TFC translate to model outcomes.”
> “Given the current evidence, TFC provides the most direct link between treatment effects and model outcomes.”
> “TFC declines at a constant absolute rate over the lifetime.”
> “AMT-130 treatment effect is based on observed impact on TFC at 48 months in the pivotal trial, and durability remains over the lifetime in the base case.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-13"></a>

#### ICER model analysis plan: target population and baseline characteristics

> “The target population for the economic evaluation will include adults with early manifest HD.”
> “The high-dose arm was chosen as a dose-dependent effect was observed and the manufacturer’s primary analyses focused on this dose.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

| Characteristic | Total | AMT-130 high dose | Enroll-HD A |
| --- | --- | --- | --- |
| Mean age | “45.21” | “45.8” | “45.2” |
| Percent male | “55.4%” | “47.1%” | “55.6%” |
| Mean Total Functional Capacity | “12.1” | “12.2” | “12.1” |

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-14"></a>

#### ICER model analysis plan: natural history input from Enroll-HD

> “Natural disease progression on usual symptomatic care will follow a simple linear regression model based on Enroll-HD cohort B TFC scores at baseline, 12, 24, 36 and 48 months, digitized from plots presented by the manufacturer in their 4-year data update.”
> “Patients’ TFC will decline at a constant rate over their lifetime following the slope of the fitted model (-0.23 TFC/year), and progress through the TFC scores over time.”
> “This matches the approach used by a previous economic model by Guzauskas et al.,”
> “with a shallower slope due to different populations.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-15"></a>

#### ICER model analysis plan: treatment effect inputs and planned scenario analyses

> “Progression on AMT-130 will follow the observed TFC trajectory up to 48 months in the pivotal trial.”
> “Afterwards, transition probabilities in the base case will follow either 1) the TFC decline rate of the usual symptomatic care arm, reduced by 61% to reflect the treatment effect on TFC observed at 48 months in the trial, or 2) rates estimated by the clinical team.”
> “Outcome-based payment arrangements for the intervention under review, which could include treatment failure rates.”
> “Modifying the treatment effect to be a 44% slowing of TFC progression on AMT-130, based on the primary outcome, composite Unified Huntington’s Disease Rating Scale (cUHDRS), from the pivotal trial.”
> “Additional scenarios modifying the natural history assumptions, treatment durability and waning treatment effects over time.”
> “Treatment of a premanifest population.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-16"></a>

#### ICER model analysis plan: mortality inputs by Shoulson and Fahn stage

> “Mortality will be based on US general population life tables, with stage-specific excess mortality for HD applied on top.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

| Parameter | 1-year probability of overall survival | Excess mortality rate from HD |
| --- | --- | --- |
| SF stage 1 | “1.000” | “0.000” |
| SF stage 2 | “0.988” | “0.008” |
| SF stage 3 | “0.967” | “0.028” |
| SF stage 4 | “0.922” | “0.075” |
| SF stage 5 | “0.859” | “0.146” |

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-17"></a>

#### ICER model analysis plan: health state utilities by Shoulson and Fahn stage

> “As utilities for stage 5 were not available, we will apply the utility for stage 4.”
> “We were unable to identify any sources for stage-specific caregiver disutilities.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

| Parameter | Value [95% CI] |
| --- | --- |
| SF stage 1 | “0.78 [0.72-0.85]” |
| SF stage 2 | “0.66 [0.59-0.73]” |
| SF stage 3 | “0.54 [0.48-0.61]” |
| SF stages 4 and 5 | “0.22 [0.11-0.32]” |

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-18"></a>

#### ICER model analysis plan: placeholder price, analyst price estimates, and administration cost

> “All costs used in the model will be updated to 2025 US dollars.”
> “Current price estimates for AMT-130 in the US range from $1,700,000 by Leerink Partners to $2,500,000 - $3,500,000 by IPD analytics.”
> “We will take $1,700,000 to be the lower value, and $3,500,000 to be the upper value, and use the midpoint of $2,600,000 as a placeholder price.”
> “We will assume an administration price of $24,138.83, based on estimates used in a previous economic model for AMT-130 by Patil et al.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-19"></a>

#### ICER model analysis plan: serious adverse event rates and costs

> “We will assume a 16.4% rate of peri-operative serious adverse events (SAE) and a 19.2% rate of treatment-related SAEs.”
> “Each will be applied as a one-time cost at the beginning of the model.”
> “The peri-operative SAE rate was calculated by pooling events across all arms receiving the surgical procedure (sham, low-dose, high-dose, dose-blinded).”
> “The treatment-related SAE was calculated by pooling treatment-related SAEs across the two high-dose arms.”
> “Costs for treatment-related SAEs will be based on CNS inflammation (n=4, MS-DRG 099).”
> “Given the model’s annual cycle length, all serious adverse events will be assumed to occur and resolve within the first cycle.”
> “Additional data on mortality and permanent harms related to the administration procedure are pending.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

| Event | Rate | Cost |
| --- | --- | --- |
| Peri-operative SAE | “16.4%” | “$10,645” |
| Peri-operative SAE component: post-lumbar puncture syndrome | “22.2%” | “$10,351” |
| Treatment-related SAE | “19.2%” | “$19,501” |

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-20"></a>

#### ICER model analysis plan: annual background health care costs by stage from U.S. Medicaid claims

> “All cause and HD-related background healthcare costs for early, middle and late stages will be sourced from Patel et al.,”
> “who conducted a retrospective cost study using Medicaid Analytic eXtract (MAX) administrative claims data from 17 states between January 1, 2010 and December 31, 2014.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

| Cost category | Early, mean (SD) | Middle, mean (SD) | Late, mean (SD) |
| --- | --- | --- | --- |
| All-cause costs | “$28,454 ($39,546)” | “$69,016 ($161,376)” | “$118,889 ($75,136)” |
| All-cause inpatient | “$4,732 ($23,882)” | “$5,311 ($13,850)” | “$85,949 ($55,241)” |
| All-cause outpatient | “$14,509 ($23,438)” | “$45,458 ($160,444)” | “$13,593 ($29,679)” |
| HD-related costs | “$12,444 ($28,673)” | “$28,064 ($45,593)” | “$82,466 ($67,642)” |
| HD-related inpatient | “$769 ($2,962)” | “$2,986 ($7,824)” | “$63,663 ($58,588)” |
| HD-related outpatient | “$5,519 ($17,680)” | “$11,318 ($33,281)” | “$6,055 ($21,301)” |
| HD-related pharmacy | “$6,156 ($22,633)” | “$13,760 ($30,473)” | “$12,748 ($32,671)” |

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-21"></a>

#### ICER model analysis plan: annual societal costs by stage

> “US based indirect costs for early, middle and late-staged HD will capture patient and caregiver work productivity, including absenteeism, early retirement and informal care costs.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

| Cost category | Early | Middle | Late |
| --- | --- | --- | --- |
| Direct nonmedical (mean) | “$2,058” | “$2,602” | “$2,294” |
| Indirect (mean) | “$85,656” | “$133,500” | “$112,816” |

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-22"></a>

#### ICER model analysis plan: model outcomes and sensitivity analyses

> “The model outcomes will also include total years of independent life (time spent in SF stages 1 & 2), and total years free of full-time care (time spent in SF stages 1-4).”
> “Probabilistic sensitivity analyses will also be performed by jointly varying all model parameters over 1,000 simulations, then calculating 95% credible range estimates for each model outcome based on the results.”
> “We will also perform threshold analyses for drug costs across a range of incremental cost-effectiveness ratios ($50,000, $100,000, $150,000, and $200,000 per QALY and evLY gained).”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-23"></a>

#### ICER model analysis plan: potential budget impact methods and threshold

> “We will use the placeholder price for AMT-130, and the threshold prices (at $50,000, $100,000, $150,000, and $200,000 per evLY gained) in our estimates of budget impact.”
> “For 2026-2027, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately $709 million per year for new drugs.”
> “All costs will be undiscounted and estimated over a five-year time horizon.”
> “The goal of the alert is to signal that the additional health care costs introduced by a new intervention may be difficult for the health care system to absorb over the short term.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-24"></a>

#### ICER model analysis plan: eligible U.S. population and uptake

> “we used inputs for the estimated prevalence of Huntington’s disease in the US (approximately 40,000 people in 2020”
> “which equals a prevalence rate of approximately 0.012%) multiplied by the estimated percent of Huntington’s disease patients in the US who are in SF stage 1 or 2 (approximately 62.7%).”
> “Applying these sources to the total US population averaged over the next five years (between years 2026-2030, approximately 342 million)”
> “results in estimates of 25,811 eligible patients in the US.”
> “For the purposes of this analysis, we will assume that 20% of these patients would initiate treatment in each of the five years, or 5,162 patients per year.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-25"></a>

#### ICER model analysis plan: exploratory preclinical population

> “To estimate this population, we will use the number of people in the US at risk for inheriting HD (approximately 200,000) multiplied by the 50% likelihood of at-risk individuals inheriting the HTT gene mutation.”
> “This calculation results in 100,000 preclinical HD patients who”
> “For the purposes of this analysis, we will assume that 20% of these patients would initiate treatment in each of the five years, or 20,000 patients per year.”

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/)

<a id="topic-4.1-26"></a>

#### ICER methods for single and short-term therapies: definition, shared savings, and durability threshold

> “therapies that are delivered through a single intervention or a short-term course (less than one year) of treatment that offer a significant potential for substantial and sustained health benefits extending throughout patients’ lifetimes.”
> “A 50/50 shared savings model in which 50% of the lifetime health system cost offsets from a new treatment are “assigned” to the health system instead of being assigned entirely to the new treatment; and”
> “A cost-offset cap model in which the health system cost offsets generated by a new treatment are capped at $150,000 per year but are otherwise assigned entirely to the new treatment.”
> “The figure of $150,000 is being selected because it is at the top of the ICER range for value-based pricing for an additional QALY.”
> “This threshold analysis may also help inform the time horizon for outcomes-based contracts should payers and manufacturers wish to use a cost-effectiveness threshold as a target for establishing fair value.”
> “We will also add caveats to these analyses noting that they may not be applicable in situations where there are outcomes-based contracts or other risk-sharing arrangements in place that are not included within these analyses.”

Source: [ICER single and short-term therapies adaptations (2022)](https://icer.org/wp-content/uploads/2022/12/ICER_SST_FinalAdaptations_122122.pdf)

<a id="topic-4.1-27"></a>

#### Analyst price and sales estimate for AMT-130

> “In June, Leerink analysts estimated that, if approved, AMT-130 would be priced at $1.7 million in the U.S. and reach $2.5 billion in worldwide sales in 2030.”

Source: [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/)

<a id="topic-4.1-28"></a>

#### uniQure potential long-term growth levers for the addressable population

> “Potential Long-term Growth Levers”
> “Increased Diagnosis Rate Due To Genetic Testing And Disease Modifying Treatment Availability”
> “Increase In Addressable Patient Segments”

Source: [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf)

<a id="topic-4.1-29"></a>

#### uniQure annual report: payer scrutiny of price and cost-effectiveness, and the CMS GENEROUS Model

> “Third-party payers and independent non-profit healthcare research organizations such as the Institute for Clinical and Economic Review are also increasingly challenging the prices charged for medical products and services and examining the medical necessity, budget-impact, and cost-effectiveness of medical products and services, in addition to their safety and efficacy.”
> “our ability to convince payers of the long-term cost-effectiveness of our therapies and, consequently, the availability of third-party coverage and adequate reimbursement;”
> “in November 2025, CMS introduced the GENEROUS Model, which is expected to launch in 2026, and which requires manufacturers to provide rebates aligned with Most Favored Nation pricing to participating state Medicaid programs that opt into the program.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-4.1-30"></a>

#### One-time gene therapy price: Zolgensma list price and installment option at approval

> “The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA), with a list price of $2.125 million, the company said.”
> “Novartis was quick to point out that the price comes out to $425,000 per year for five years, which is also far less”
> “than the 10-year cost of current chronic SMA therapy.”
> “Novartis’ AveXis, which developed the drug, is also “working closely with payers” to create five-year outcomes-based pacts and pay-over-time options for payers”

Source: [Helfand (2019)](https://www.fiercepharma.com/pharma/novartis-slaps-2m-plus-pricetag-newly-approved-gene-therapy-zolgensma)

<a id="topic-4.1-31"></a>

#### Gene therapy price: Hemgenix list price and the ICER placeholder price and cost-offset cap analysis

> “CSL Behring, a CSL business, will begin commercializing Hemgenix as soon as possible in the United States with a list price of $3.5 million, according to a company spokesperson.”
> “ICER had used a placeholder price of $4 million in its analysis of etranacogene dezaparvovec and capped the offset costs at $150,000 a year.”
> “They found that to be cost-effective and achieve a Health Benefit Price Benchmark (HBPB), etranacogene dezaparvovec would need to be priced at $2.93 million to $2.96 million.”

Source: [Myshko (2022)](https://www.managedhealthcareexecutive.com/view/fda-approves-gene-therapy-for-hemophilia-b)

<a id="topic-4.1-32"></a>

#### Gene therapy price: Roctavian wholesale acquisition cost and outcomes-based warranty

> “Roctavian, which will available in about eight weeks, will have a wholesale acquisition cost of $2.9 million based on the weight of a typical patient, the company said in an investor call.”
> “BioMarin is offering an outcomes-based warranty that will reimburse government and commercial payers up to 100% of wholesale acquisition cost in the event that a person does not respond to Roctavian.”
> “If an individual treated with Rocktavian loses response at any time in the first four years after dosing, BioMarin will reimburse payers on a prorated basis for the cost of treatment.”

Source: [Myshko (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-2-9-million-gene-therapy-for-hemophilia-a)

<a id="topic-4.1-33"></a>

#### Roctavian market withdrawal

> “BioMarin Pharmaceutical Inc. today announced that it will voluntarily remove ROCTAVIAN® (valoctocogene roxaparvovec-rvox) from the market.”
> “Despite BioMarin’s efforts, the company was unable to identify a qualified buyer.”
> “The company will maintain its commercial patient support program and honor existing outcomes-based agreements with payers.”

Source: [BioMarin statement, ROCTAVIAN market withdrawal (2026)](https://www.biomarin.com/news/company-statements/biomarin-voluntarily-withdraws-roctavian-from-the-market/)

<a id="topic-4.1-34"></a>

#### Gene therapy price: Elevidys wholesale acquisition cost

> “The first FDA-approved gene therapy to treat Duchenne muscular dystrophy (DMD), Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl), will have a wholesale acquisition cost (WAC) of $3.2 million.”
> “The WAC price is similar to other gene therapies, which range from $2.1 million to $3.5 million, Arash Sadeghi, clinical pharmacist for Optum Rx, told FormularyWatch.”

Source: [Blank (2023)](https://www.managedhealthcareexecutive.com/view/first-gene-therapy-for-duchenne-priced-at-3-2-million)

<a id="topic-4.1-35"></a>

#### Gene therapy price: eladocagene exuparvovec-tneq wholesale acquisition cost in the USA, stereotactic administration cost, and cost per QALY in a PTC Therapeutics-funded analysis

> “For costing of eladocagene exuparvovec-tneq treatment, the list price (wholesale acquisition cost, WAC) in the USA of $3,950,000”
> “The cost of administration, $106,030, is a proxy value for the cost of the stereotactic procedure”
> “Incremental cost per QALY ranged from $199,007–$224,104.”
> “This study was funded by PTC Therapeutics Inc.”

Source: [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799622/)

<a id="topic-4.1-36"></a>

#### Gene therapy price: Beqvez

> “Bequez will be priced at $3.5 million, which is in line with the previously approved gene therapy for hemophilia B Hemgenix.”
> “A Pfizer spokesperson said the price is based on a holistic view of its value, including the benefits generated for patients, healthcare systems, and society.”

Source: [Myshko (2024)](https://www.managedhealthcareexecutive.com/view/fda-approves-pfizer-s-gene-therapy-for-beqvez-for-hemophilia)

<a id="topic-4.1-37"></a>

#### Beqvez discontinuation

> “The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the gene therapy to treat hemophilia B.”
> “The one-time treatment carried a list price of $3.5 million per person.”
> “Several reasons led to the discontinuation, including limited interest from patients and doctors toward hemophilia gene therapies to date, a Pfizer spokesperson told Fierce Pharma in a statement.”

Source: [Liu (2025)](https://www.fiercepharma.com/pharma/pfizer-empties-gene-therapy-portfolio-discontinues-hemophilia-treatment-beqvez)

<a id="topic-4.1-38"></a>

#### Payment models for gene therapy: Beqvez warranty program

> “With BEQVEZ now approved for use, Pfizer is launching an innovative warranty program based on durability of patient response to treatment.”
> “The goal of the warranty is to provide greater certainty to payers, maximize access for eligible patients who receive BEQVEZ, and offer financial protection by insuring against the risk of efficacy failure.”

Source: [Pfizer press release, BEQVEZ approval (2024)](https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec)

<a id="topic-4.1-39"></a>

#### Payment models for gene therapy: Hemgenix value-based arrangement offered to commercial and government payers

> “Hemgenix (etranacogene dezaparvovec) gene therapy for hemophilia B, has a price tag of $3.5 million, and Roctavian (valoctocogene roxaparvovec) for hemophilia A, costs $2.9 million.”
> “CSL Behring is having conversations about value-based arrangements with commercial and government payers who are interested in this model,”
> “Under this value-based arrangement, we will offer a substantial rebate to the payers if patients return to using prophylactic factor IX during the first 3 1/2 years following infusion.”

Source: [Hagen (2023)](https://www.managedhealthcareexecutive.com/view/manufacturers-adopt-no-cure-no-pay-pricing-for-hemophilia-gene-therapy)

<a id="topic-4.1-40"></a>

#### Payment models for gene therapy: value-based contracts, warranties, and short-term budget impact for U.S. payers

> “Value-based contracts fall broadly into three categories: milestone-based rebates, warranties and performance-based installment payments (sometimes referred to as an annuity).”
> “First, patients treated with gene therapies may change insurers during the term of any payment contract, greatly complicating efforts to track outcomes and link them to additional rebates, a warranty, or performance-based installment payments.”
> “A third barrier, Medicaid Best Price (MBP) provisions, applies to all value-based contracts except warranties”
> “For example, Roctavian™ launched with an outcomes-based warranty offered to all US insurers, which will reimburse payers on a pro-rated basis over the first 4 years from the time of dosing if the patient loses response – up to 100% of wholesale acquisition”
> “For these payers, an unpredictable $1–3 million treatment may be such a large percentage of their annual health costs that an upfront payment would be financially destabilizing.”
> “All told, 85 new gene therapies across more than 12 therapeutic areas are expected to receive regulatory approval by 2032, with an estimated ten-year list price spend of $35 to $40 billion”

Source: [Phares et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11609966/)

<a id="topic-4.1-41"></a>

#### Payment models for gene therapy: CMS Cell and Gene Therapy Access Model

> “It is a multi-year, voluntary model for states and manufacturers to test whether a CMS-led approach to developing and administering outcomes-based agreements (OBAs) for cell and gene therapies increases Medicaid beneficiaries’ access to innovative treatment, improves their health outcomes, and reduces health care costs and burden to state Medicaid programs.”
> “The initial focus of the model is on access to gene therapy treatments for people living with sickle cell disease, a genetic blood disorder.”
> “States began participation between January 2025 and January 2026.”
> “Number of State Participants: 34”
> “Number of Manufacturer Participants: 2”

Source: [CMS Cell and Gene Therapy Access Model (2026)](https://www.cms.gov/priorities/innovation/innovation-models/cgt)

<a id="topic-4.1-42"></a>

#### Budget impact of etranacogene dezaparvovec in a hypothetical 1-million-member health plan, funded by CSL Behring

> “The model considered a hypothetical 1-million-member plan over a 5-year horizon.”
> “In the 1-million-member health plan, an estimated 1.8 PwHB were eligible for treatment with etranacogene dezaparvovec.”
> “Gradual uptake of etranacogene dezaparvovec resulted in cumulative 5-year budget impact of $848,509 compared with a scenario without etranacogene dezaparvovec.”
> “In years 1-5, the incremental annual and per-member per-month costs ranged from $79,824 to $271,435 and from $0.007 to $0.023, respectively.”
> “Etranacogene dezaparvovec price was assumed to be $3,500,000 as a single administration (Table 2).”
> “For the analysis assuming 100% uptake of etranacogene dezaparvovec in year 1, incremental annual cost of $4.843 million (Figure 2A) or $0.40 PMPM”
> “Scenario analyses (Table 3) showed that the 5-year budget impact results were sensitive only to the assumptions regarding uptake of etranacogene dezaparvovec.”
> “This study was conducted by RTI Health Solutions and funded by CSL Behring LLC.”

Source: [Wilson et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293766/)

<a id="topic-4.1-43"></a>

#### U.S. cost-effectiveness analysis of tominersen and AMT-130 in early-stage HD

> “A Markov model with four health states (early, middle, late, and death) was developed to estimate lifetime costs and benefits from a modified societal perspective, with death as an absorbing state.”
> “As per the incremental cost-effectiveness ratio (ICER) value assessment framework, a willingness-to-pay threshold (WTP) of $500,000/QALY gained was considered given that HD is a rare disease.”
> “Compared with SoC, Tominersen increased costs by $2.11 million and QALYs by 0.93, resulting in an ICER of $2.28 million per QALY gained, whereas AMT-130 increased costs by $1.49 million and QALYs by 5.23, resulting in an ICER of $285,703 per QALY gained in the base case.”
> “Probabilistic analysis showed AMT-130 had 80% probability of being cost-effective at $350,000/QALY gained.”
> “Further evidence on long-term effectiveness and durability is needed to inform policy and reimbursement decisions.”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-44"></a>

#### U.S. cost-effectiveness analysis of tominersen and AMT-130: model structure, perspective, and time horizon

> “A modified societal perspective was adopted to capture direct healthcare costs and non-healthcare costs such as caregiver burden.”
> “The cycle length was 1 year with an annual discount rate of 3% used for all future costs and utilities.”
> “a total of 30 annual cycles were considered sufficient to capture lifetime costs and health outcomes associated with the disease.”
> “All patients entered the model in the early stage, and at the end of each cycle, they could transition into a different health stage, stay in the early stage, or experience death”
> “For Tominersen, we postulated that even though the drug would result in slowing the disease progression, it would not result in disease reversal. Therefore, we made an assumption on the basis of expert opinion that the probability of disease progression from the early stage to the middle stage would reduce from 0.16 to 0.1 for the base-case model”
> “Utilities for Tominersen and AMT-130 were assumed equal to SoC because trial-based utility data are not yet available.”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-45"></a>

#### U.S. cost-effectiveness analysis: standard of care inputs by disease stage

| Input | Base case | Range |
| --- | --- | --- |
| Transition probability, early to middle | “0.16” | “0.1–0.2” |
| Transition probability, middle to late | “0.32” | “0.3–0.4” |
| Mortality rate, early to death | “0.01” | “0–0.05” |
| Mortality rate, middle to death | “0.03” | “0–0.05” |
| Mortality rate, late to death | “0.1” | “0–0.15” |
| Early stage, inpatient cost | “$1067” | “$1044–1091” |
| Early stage, outpatient cost | “$3962” | “$3878–4047” |
| Early stage, pharmacy cost | “$11,124” | “$10,705–11,544” |
| Early stage, caregiver cost | “$6120” | “$6117–6124” |
| Middle stage, inpatient cost | “$4492” | “$4456–4528” |
| Middle stage, outpatient cost | “$10,356” | “$10,293–10,420” |
| Middle stage, pharmacy cost | “$13,001” | “$12,633–13,370” |
| Middle stage, caregiver cost | “$38,380” | “$33,756–43,004” |
| Late stage, inpatient cost | “$19,188” | “$18,933–19,444” |
| Late stage, outpatient cost | “$17,942” | “$17,621–18,263” |
| Late stage, pharmacy cost | “$19,283” | “$18,909–19,657” |
| Late stage, caregiver cost | “$112,287” | “$82,119–142,454” |
| Utility, early stage | “0.73” | “0.7–0.9” |
| Utility, middle stage | “0.63” | “0.5–0.7” |
| Utility, late stage | “0.57” | “0.4–0.6” |

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-46"></a>

#### U.S. cost-effectiveness analysis: drug price and administration cost assumptions

> “Since Tominersen and AMT-130 are currently in clinical trials, we lacked established cost data and therefore relied on cost estimates from treatments for spinal muscular atrophy (SMA).”
> “After accounting for the discount, the estimated cost of a single 60 mg injection of Tominersen was $106,250.”
> “Based on this schedule, the estimated annual cost of Tominersen was $318,750.”
> “Considering these similarities, the cost for AMT-130 was assumed to be the same as the list price for Zolgensma”
> “The regular payer discount of 15% was then applied to the list price, for a one-time dose of AMT-130, which was estimated to be $1,806,250.”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

| Treatment arm input | Base case | Range |
| --- | --- | --- |
| Tominersen, early to middle transition probability | “0.10” | “0–0.16” |
| AMT-130, early to middle transition probability | “0” | “0–0.16” |
| Tominersen, adverse events rate | “0.4” | “0.3–0.5” |
| AMT-130, adverse events rate | “0.2” | “0.1–0.3” |
| Tominersen, annual drug cost: 3 intrathecal injections of 60 mg (low dose) | “$318,750” | “$207,188–375,000” |
| Tominersen, adverse event | “$24,443” | “$21,998–26,887” |
| AMT-130, one-time drug cost (low dose) | “$1,806,250” | “$1,381,250–2,125,000” |
| AMT-130, adverse event | “$22,215” | “$19,994–24,437” |

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

| Treatment arm administration cost | Base case |
| --- | --- |
| Tominersen | “$3627” |
| AMT-130 | “$23,516” |

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-47"></a>

#### U.S. cost-effectiveness analysis: base-case results

| Intervention | Total cost | Total QALYs | Incremental cost | Incremental QALYs | ICER ($/QALY gained) |
| --- | --- | --- | --- | --- | --- |
| Standard of care | “$685,662” | “6.11” | “–” | “–” | “–” |
| Tominersen | “$2,795,956” | “7.03” | “$2,110,294” | “0.93” | “$2,280,427” |
| AMT-130 | “$2,180,147” | “11.34” | “$1,494,484” | “5.23” | “$285,703” |

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-48"></a>

#### U.S. cost-effectiveness analysis: scenario and sensitivity analyses

> “After considering the additional value of hope to the base-case utility value, the total QALYs for Tominersen increased from 7.03 to 7.49, and for AMT-130, it increased from 11.34 to 12.43.”
> “As a result, the ICER value decreased significantly from $2.28 million per QALY gained to $1.52 million per QALY gained for Tominersen, and for AMT-130, it changed from $285,703 per QALY gained to $236,540 per QALY gained.”
> “One-way sensitivity analyses indicated that the ICERs were most sensitive to the cost of the drugs, particularly AMT-130 and Tominersen, as well as health-state utility values for early and middle-stage HD.”
> “The cost-effectiveness acceptability curve revealed that the probability of AMT-130 being considered cost-effective at a WTP threshold of $250,000 per QALY gained was 30%”
> “The probability of Tominersen being considered cost-effective was 0% throughout the curve”
> “Findings from the PSA also indicated that the probability of both of the treatments being considered cost-effective was 0% at the conventional WTP threshold of $100,000–150,000 per QALY gained.”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-49"></a>

#### U.S. cost-effectiveness analysis: stated limitations

> “The model relied on many assumptions and simplifications owing to limited clinical trial evidence and the lack of established cost data for Tominersen and AMT-130.”
> “The model relied heavily on the assumption of sustained benefit for both treatments beyond the data.”
> “The statistical generalizability or the comparative efficacy of AMT-130 and Tominersen with the SoC cannot be assessed.”
> “Additionally, it should be noted that the Tominersen trial recently updated its protocol to continue only the 100-mg dose”

Source: [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/)

<a id="topic-4.1-50"></a>

#### U.S. decision-modeling framework for future disease-modifying treatments

> “The lifetime costs of HD were $508,200 ($310,300 to $803,700) for the PFD population, $1.15 million ($684,500 to $1.89 million) for SF1 individuals, and $1.07 million ($571,700 to $2.26 million) for SF2 individuals.”
> “Recent research estimates that annual costs associated with HD in the United States ranges from $6,600 to $30,300 per year depending on the stage of progression.”
> “Furthermore, the DMTs currently under development vary in mechanism of action (small molecule, ASO, gene therapy), route of administration (oral, intrathecal, intraparenchymal), and once vs recurrent therapy; these contingencies make it difficult at this time to assign a DMT price in our exploratory analysis.”

Source: [Guzauskas et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11332983/)

<a id="topic-4.1-51"></a>

#### United Kingdom progression model with societal cost estimation

> “Data from the Enroll-HD observational study were used to fit a continuous-time hidden Markov disease progression model, which identified five distinct states.”
> “Finally, the results of the UK cost modelling show that indirect costs of HD such as state benefits and lost gross domestic product contribution could be the driving factors for the societal cost, over and above health and social care costs.”

Source: [Pollard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11576117/)

<a id="topic-4.1-52"></a>

#### Health technology assessment: ICER assessment of AMT-130 announced

> “The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of ifezuntrigene inilparvovec (uniQure N.V.) for Huntington’s disease.”
> “The assessment will be publicly discussed during a meeting of the Midwest Comparative Effectiveness Public Advisory Council (CEPAC) in March 2027, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.”

Source: [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-gene-therapy-for-huntingtons-disease/)

<a id="topic-4.1-53"></a>

#### Health technology assessment: ICER draft scope for population, comparator, and planned models

> “The population of focus for the review is adults with early symptomatic Huntington’s disease.”
> “As a complement to the evidence review, we will develop an economic model to assess the lifetime cost-effectiveness of AMT-130 relative to usual symptomatic care.”
> “The base case analysis will take a health care system perspective (i.e., focus on direct medical care costs only).”
> “The model will consist of health states capturing distinct levels of clinical progression, based on Total Functional Capacity (TFC) scores.”
> “In separate analyses, we will explore the potential health care system budgetary impact of treatment over a five-year time horizon, utilizing published or otherwise publicly available information on the potential population eligible for treatment and results from the economic model for treatment costs and cost offsets.”
> “A detailed economic model analysis plan with proposed methodology, model structure, model parameters, model inputs, and model assumptions will be published on November 16, 2026.”

Source: [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf)

<a id="topic-4.1-54"></a>

#### United States all-state closed claims: annual prevalence of diagnosed Huntington's disease per 100,000, 2020 to 2024

> “Of the 59 million individuals in the study population, 38.4 million (65.1%) met the continuous enrollment requirement of 12 months during the study period.”

Source: [Frisch et al. (2026)](https://www.jmir.org/2026/1/e100284)

| Year | Prevalence rate per 100,000 (95% CI) |
| --- | --- |
| 2020 | “6.7 (6.3-7.1)” |
| 2021 | “7.4 (7.0-7.8)” |
| 2022 | “7.9 (7.5-8.3)” |
| 2023 | “8.4 (8.0-8.8)” |
| 2024 | “9.4 (8.9-9.8)” |

Source: [Frisch et al. (2026)](https://www.jmir.org/2026/1/e100284)

<a id="topic-4.1-55"></a>

#### British Columbia: multisource prevalence of Huntington's disease

> “Prevalence of HD was estimated at 13.7 per 100,000 (95% confidence interval [CI]: 12.6-14.8 per 100,000) in the general population, and 17.2 per 100,000 (95% CI: 15.8-18.6 per 100,000) in the Caucasian population.”

Source: [Fisher and Hayden (2014)](https://pubmed.ncbi.nlm.nih.gov/24151181/)

<a id="topic-4.1-56"></a>

#### United States commercial claims: share of diagnosed people aged 20 years or younger

> “Among those diagnosed, 1.18% (n = 44) were identified as 20 years old or less, indicating juvenile onset.”

Source: [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/)

<a id="topic-4.1-57"></a>

#### North American Enroll-HD participants with manifest Huntington's disease: Total Functional Capacity stage

> “Most participants were in TFC stages I–III, with the highest proportion (41.3%) of participants in stage II (Table 1).”

Source: [Furr Stimming et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089624/)

| Stage (Total Functional Capacity score) | Participants |
| --- | --- |
| Stage I (11 to 13) | “n = 845” |
| Stage II (7 to 10) | “n = 1068” |
| Stage III (3 to 6) | “n = 540” |
| Stage IV (1 to 2) | “n = 116” |
| Stage V (0) | “n = 15” |

Source: [Furr Stimming et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12089624/)

<a id="topic-4.1-58"></a>

#### Pooled incidence of Huntington's disease

> “Pooled incidence was 0.48 cases per 100,000 person-years (95% CI, 0.33-0.63).”

Source: [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/)

<a id="topic-4.1-59"></a>

#### United Kingdom primary care: median survival from first recorded diagnosis

> “The KM survival curve (Figure 1) shows a median survival time of 12.4 years (95% CI 10.6–15.2).”

Source: [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/)

<a id="topic-4.1-60"></a>

#### Colorado all-payer claims: share of people with Huntington's disease seen by a neurologist in a calendar year

> “Approximately half (49.9%) received neurologist care, with 33.8% seeing a MDS during the given calendar year.”

Source: [Ogilvie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13316193/)

<a id="heading-4.2"></a>

### 4.2 Budget Impact Model

<a id="heading-4.2.1"></a>

#### 4.2.1 Approach and Framework

No evidence found.

<a id="heading-4.2.2"></a>

#### 4.2.2 Perspective and Time Frame

No evidence found.

<a id="heading-4.2.3"></a>

#### 4.2.3 Epidemiology and Eligible Population Inputs

No evidence found.

<a id="heading-4.2.4"></a>

#### 4.2.4 Cost Assumptions

No evidence found.

<a id="heading-4.2.5"></a>

#### 4.2.5 Model Outcomes

No evidence found.

<a id="heading-4.2.6"></a>

#### 4.2.6 Results

<a id="heading-4.2.6.1"></a>

##### 4.2.6.1 Base Case

No evidence found.

<a id="heading-4.2.6.2"></a>

##### 4.2.6.2 Scenario Analyses

No evidence found.

<a id="heading-4.2.7"></a>

#### 4.2.7 Budget impact model discussion

No evidence found.

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
